Listen

Goals

  • To find early diagnostic indicators that can accurately identify patients with localized tumors, who are likely to benefit from curative treatment, while avoiding unnecessary biopsies or more agressive management. 
  • To develop and evaluate new diagnostic and treatment modalities with better efficacy and tolerability outcomes. 
  • To find pre- and on-treatment biomarkers to identify patients likely to respond to specific therapies. 
  • To optimize the risk-benefit ratio of available anti-cancer drugs through early identification of non-responders, pharmalogical interventions and dose individualization. 
  • To identify host-related risk factors to guide strategies for primary and tertiary prevention.


go to main content
Research Research programs Prostate, bladder and kidney cancer

Our mission

We aim to improve outcomes and quality of life for patients with prostate, bladder or kidney cancer.

Goals

See some of the most important goals for this research program.

read more

Research groups contributing to this research program

Biomedical magnetic resonance

Tom Scheenen's research group develops, implement, and test new MR imaging and spectroscopy technology at clinical and ultra-high magnetic field MR scanners. 

Cancer pharmacology

Nielka van Erp's research group focuses on describing, explaining, understanding and modifying the pharmacokinetics of oral anticancer drugs.

Epidemiology

Bart Kiemeney's research group aims to improve the diagnosis and treatment of urological cancers using observational and experimental designs.

Spokesperson(s) for this research program

Spokesperson

prof. dr. ir. Tom Scheenen

contact form